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Abstract 
Background: Extensive studies have confirmed the efficacy of taxanes in combination with anthracycline‑based 
chemotherapy on breast cancer. However, few studies have assessed the efficacy of weekly taxane–anthracycline 
regimens on locally advanced breast cancer. This study was to compare the efficacy and safety of a weekly taxane–
anthracycline regimen with those of tri‑weekly anthracycline‑based regimen in patients with locally advanced breast 
cancer.
Methods: Patients with locally advanced breast cancer were randomized to receive 4–6 cycles of neoadjuvant chem‑
otherapy with tri‑weekly 5‑fluorouracil–epirubicin–cyclophosphamide (FEC) regimen or weekly paclitaxel–epirubicin 
(PE) regimen. The primary endpoint was the pathologic complete response (pCR) rate. Other endpoints included the 
clinical tumor response, breast‑conserving surgery rate, and adverse events.
Results: Between March 2010 and September 2013, 293 patients were randomized to the FEC (n = 151) and PE 
(n = 142) arms. The overall clinical response rate was significantly higher in the PE arm than in the FEC arm (76.06% vs. 
59.95%, P = 0.001). Consistently, the post‑chemotherapy pathologic T and N stages were significantly lower in the PE 
arm than in the FEC arm (P < 0.001). However, the pCR rate was similar in the two arms (10.61% vs. 12.31%, P = 0.665). 
Overall, 36 (27.27%) patients in the FEC arm and 6 (35.28%) in the PE arm were qualified for breast‑conserving surgery. 
Most adverse events were comparable in both arms, with more severe neutropenia in the PE arm than in the FEC arm 
(11.97% vs. 5.96%, P = 0.031).
Conclusions: In patients with locally advanced breast cancer, weekly PE was not superior to FEC in terms of pCR. 
However, weekly PE has a higher response rate and superior down‑staging effects. On this account, the PE regimen 
may be considered an alternative option for locally advanced breast cancer. Long‑term follow‑up data are needed to 
confirm the efficacy of this regimen on locally advanced breast cancer.
Trial registration Chinese clinical trial registry, ChiCTR‑TRC‑10001043, September 21, 2014
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Background
Locally advanced breast cancer is a heterogeneous entity 
that includes advanced primary tumors, extensive nodal 
involvement, and inflammatory breast cancer [1, 2]. 
Despite the progress in understanding tumor biology and 
the development of targeted therapy, locally advanced 
breast cancer remains a major clinical challenge with an 
unfavorable prognosis [1]. Neoadjuvant chemotherapy 
(NACT) is a standard treatment of locally advanced 
breast cancer [3, 4]. Women who achieved a pathologic 
complete response (pCR) during NACT had prolonged 
survival compared with those who did not achieved pCR 
[5].
Anthracycline-based regimens are the most effective 
chemotherapy for breast cancer [6]. Anthracycline-based 
regimens, such as tri-weekly 5-fluorouracil–epirubicin–
cyclophosphamide (FEC) regimen, is widely recommend 
by guidelines and used in clinical practice. The addition 
of taxanes to anthracycline-based regimens has been 
shown to enhance antitumor activity with increased pCR 
and breast-conserving surgery (BCS) rate as well as pro-
longed survival [7, 8]. In addition, the Eastern Coopera-
tive Oncology Group (ECOG) 1199 trial demonstrated 
a significant disease-free survival benefit of weekly 
paclitaxel [9, 10]. Theoretically, the ideal chemotherapy 
regimen should be safe, effective, and simple. For these 
reasons, weekly paclitaxel–epirubicin (PE) regimen is 
attractive. In addition, considering the mild myelosup-
pressive effect of paclitaxel, weekly PE could be a conven-
ient outpatient chemotherapy regimen.
Till now, extensive studies have evaluated the thera-
peutic value of taxanes in combination with anthracy-
cline-based chemotherapy in breast cancer; however, 
limited data are available to evaluate its efficacy on locally 
advanced breast cancer, especially in Chinese women. In 
this prospective randomized controlled trial, we com-
pared the safety and efficacy of a weekly PE regimen with 
those of the tri-weekly FEC regimen in Chinese women 
with locally advanced breast cancer.
Patients and methods
Participant enrollment
This prospective randomized controlled trial was 
approved by the Ethics Committee of West China Hospi-
tal of Sichuan University. Written informed consent was 
obtained from all participants. The study was registered 
with the Chinese Clinical Trial Register on September 21, 
2014 (Registration number: ChiCTR-TRC-10001043).
Women aged 18–70  years old with locally advanced 
breast cancer confirmed by core needle biopsy were 
eligible for our study. Locally advanced breast cancer 
was classified as clinical stage IIB or III according to 
the American Joint Committee on Cancer staging sys-
tem. Before randomization, baseline chest radiography, 
abdominal computed tomography (CT) or magnetic 
resonance imaging, and bone scintigraphy were per-
formed to exclude distant metastases. Other eligibility 
criteria were an ECOG performance status of 0–1; nor-
mal cardiac function; no history or evidence of abnor-
mal hematologic, renal, or hepatic function; and no 
history of other neoplasm (except non-melanoma skin 
cancer or curatively treated carcinoma in  situ of the 
cervix).
Patients were excluded if they were pregnant; had 
received prior breast cancer surgery or systemic therapy; 
had uncontrolled concurrent illness such as serious viral, 
bacterial, or fungal infections, peptic ulcers or diabetes, 
or autoimmune diseases; had a history of severe hyper-
sensitivity reactions to chemotherapeutic regimens; or 
had any other illness deemed by the physician to affect 
chemotherapy tolerability.
Treatment
With simple randomization, the participants were ran-
domly assigned to the PE arm or the FEC arm. In the PE 
arm, intravenous infusion of epirubicin 30–40  mg/m2 
and paclitaxel 70–80  mg/m2 were administered concur-
rently on days 1, 8, and 15 of every 4-week cycle. In the 
FEC arm, intravenous infusion of 5-fluorouracil 500 mg/
m2, epirubicin 100  mg/m2, and cyclophosphamide 
500 mg/m2 were administered on day 1 of every 3-week 
cycle. Antimimetic drugs were administered prophylac-
tically 30 min before the chemotherapeutic regimen was 
administered. During NACT, granulocyte colony-stimu-
lating factor (G-CSF) support was required if the neutro-
cyte count dropped to <1.0 × 109/L.
Surgery was undertaken within 1–2  weeks of NACT 
completion. According to the tumor characteristics and 
patient preference, women underwent BCS or mastec-
tomy. Those considered eligible for BCS had a single 
tumor <3  cm in diameter, with the distance between 
the tumor edge and nipple being ≥3 cm, had no diffuse 
lesion or skin involvement, and were not contraindicated 
for radiotherapy. All patients who underwent BCS also 
underwent postoperative radiotherapy. All these patients 
underwent axillary lymph node dissection for nodal 
assessment.
All study visits were completed at the Breast Cancer 
Center of West China Hospital. At the beginning of each 
cycle, history taking, physical examination, and hemato-
logic assessment were conducted to evaluate safety. The 
NACT schedule was delayed if the left ventricle ejec-
tion fraction (LVEF) decreased by 15% or if the patient 
showed symptoms of congestive heart failure, a severe 
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hypersensitive reaction, or other adverse events dur-
ing treatment. In the PE arm, if the patients had severe 
neutropenia (neutrophil count <1.0 × 109/L), febrile neu-
tropenia (grade 2 and above), or peripheral neuropathy 
(grade 2 and above), the dose of epirubicin and paclitaxel 
was reduced by 15%.
Participants were withdrawn if they had disease pro-
gression or developed severe adverse events (e.g., grade 3 
or 4 non-hematologic toxicity), or at their request.
Efficacy assessments
Physical examination and imaging data (ultrasonog-
raphy for tumor response assessment and CT scan for 
metastasis monitoring) were carefully recorded for clini-
cal assessments before treatment, every two cycles dur-
ing NACT, and before surgery. The tumor response was 
assessed by experienced oncologists and was classified 
as clinical complete response (cCR), partial response 
(cPR), stable disease (cSD), or progressive disease (cPD). 
In particular, the clinical tumor response was defined as 
the achievement of cCR and cPR. Any controversy was 
solved by discussion with a third oncologist. Tumor 
responses were used to dictate management strategies. 
Those showing a cCR, defined as the disappearance of the 
breast tumor and enlarged nodes on clinical assessments, 
could undergo surgery. Those showing a cPR, defined 
as a reduction of ≥30% in the three largest perpendicu-
lar tumor diameters, could complete at least four NACT 
cycles and then undergo surgery. Those with cSD, defined 
as a tumor reduction of <30%, or those with cPD, defined 
as an increase of ≥20% in the target tumor diameter or 
the emergence of a new tumor, could switch NACT regi-
mens or undergo surgery as desired.
Postoperative pathologic assessments were conducted 
by pathologists at the Pathology Department of West 
China Hospital. A pCR was defined as the complete dis-
appearance of the invasive tumor in the breast and lymph 
nodes. Residual ductal carcinoma in  situ (DCIS) alone 
was also classified as pCR. Before the assessments and 
data analysis, the two groups were renamed as group 1 or 
2 without detailed information on the NACT provided. 
Therefore, the surgeons who assessed the suitability for 
BCS, the pathologists who assessed the postoperative 
specimens, and the statisticians who performed the anal-
ysis were all blinded.
Safety assessments
All adverse events were recorded and graded according 
to the National Cancer Institute Common Toxicity Cri-
teria (version 2.0). All women who underwent at least 1 
cycle of chemotherapy were included in the safety analy-
sis. Only grade 3–4 adverse events were analyzed.
Statistical analyses
The sample size was estimated to detect a pCR rate dif-
ference of 25% for the PE arm and 10% for the FEC arm. 
The assumed dropout rate was 10%. A sample size of 
218 participants was sufficient to provide an 80% power 
to detect a pCR improvement of 15% in each arm with a 
type I error rate of 0.05.
All data were analyzed based on the intent-to-treat 
principle at randomization. Descriptive data were used 
to analyze patient characteristics. Quantitative data 
were compared using an independent sample t test, and 
qualitative data were compared using the Chi square test. 
Ranked data were compared using a non-parametric test. 
Statistical tests were considered significant with a two-
sided P value of <0.05. All data were analyzed using SPSS 
version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The results of randomization and treatment assignment 
are shown in Fig.  1. Between March 2010 and Septem-
ber 2013, 300 patients were enrolled, but 7 of them with-
drew prior to treatment. Of the remaining 293 patients, 
151 were assigned to the FEC arm, and 142 were assigned 
to the PE arm. The baseline patient characteristics of 
the two groups were evenly matched and are shown in 
Table 1. The median ages were 47 (range 27–69) years for 
the FEC arm and 47 (range 24–68) years for the PE arm. 
During chemotherapy, 16 patients (10 in the FEC arm 
and 6 in the PE arm) had declined further treatment; 15 
(9 in the FEC arm and 6 in the PE arm) were lost to fol-
low-up; and 34 (22 in the FEC arm and 12 in the PE arm) 
had switched chemotherapy regimens due to unsatisfac-
tory outcomes or toxicities.
Clinical response
During chemotherapy, three assessments were performed 
to grade the clinical response to these two regimens 
(Table 2). The results of the last assessment for individual 
participants are shown in Fig.  2. The clinical response 
rates were significantly higher in the PE arm than in the 
FEC arm (76.55% vs. 56.95%, P = 0.001). Those in the PE 
arm achieved higher cPR and lower cSD rates than those 
in the FEC arm (cPR rate: 70.92% vs. 54.30%, P = 0.006; 
cSD rate: 14.79% vs. 30.46% P = 0.002). Two patients in 
the PE arm developed distant metastasis after 4 cycles of 
NACT.
For each participant, the tumor was restaged at the last 
assessment. As shown in Table  3, both regimens exhib-
ited excellent down-staging effects (both P < 0.001), with 
the PE regimen exhibiting a superior down-staging effect 
compared with the FEC regimen (P = 0.026).
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Surgery and pathologic response
Among the 293 patients, 262 underwent surgery (132 in 
the FEC arm and 130 in the PE arm). Among them, 219 
patients (114 in the FEC arm and 105 in the PE arm) had 
completed at least 4 cycles of NACT; 33 (22 in the FEC 
arm and 11 in the PE arm) had switched chemotherapy 
regimens.
Surgery information is shown in Table 4. No significant 
difference was observed in the BCS rate. Theoretically, 36 
(27.27%) patients in the FEC arm and 6 (35.38%) in the 
PE arm were candidates for BCS (P =  0.157). However, 
only 3 (2.27%) in the FEC arm and 4 (3.08%) in the PE 
arm underwent BCS (P = 0.721).
For pathologic response assessments, all the 262 
patients were included in the intention-to-treat analy-
sis. Postoperative pathologic staging indicated that the 
weekly PE regimen significantly alleviated tumor bur-
den in patients with locally advanced breast cancer as 
compared with the tri-weekly FEC regimen (P =  0.001) 
(Table  5). However, no significant differences between 
the FEC and PE arms were observed in the overall pCR 
(pCR in both the breast and lymph nodes) rates (10.61% 
vs. 12.31%, P = 0.665), the breast pCR rates (13.64% vs. 
16.92%, P  =  0.460), or regional lymph node pCR rates 
(34.85% vs. 39.23%, P = 0.463).
Safety
For the safety analysis, we evaluated only grade 3–4 
adverse events, which are listed in Table  6. Both 
the FEC and PE regimens were well tolerated, and 
all adverse events were manageable. The frequency 
of neutropenia was higher in the PE arm than in the 
FEC arm (P  =  0.031). Four patients (2 in each arm) 
had grade 4 neutropenia and were treated by repeated 
G-CSF administration. Three patients (2 in the FEC 
arm and 1 in the PE arms) had liver damage and 
required breast cancer surgery after 3 or 4 cycles of 
NACT. One patient had grade 4 bone marrow suppres-
sion after 1 cycle of PE and thus switched to the FEC 
regimen. There were no cardiac events or treatment-
related deaths during the study period. Other adverse 
events were mild and slightly affected patient quality 
of life during NACT.
Discussion
Our results showed that the weekly PE regimen was not 
superior to the tri-weekly FEC regimen in treating locally 
advanced breast cancer in terms of pCR. However, in the 
NACT setting, the weekly PE regimen showed significant 
value in the clinical tumor response and down-staging 
effect.
3rd clinical assessment
(5-6 cycles of NACT)
2nd clinical assessment
(3-4 cycles of NACT)
1st clinical assessment
(1-2 cycles of NACT)



















Switched regimens: n = 5#
Required surgery (3 cycles): n = 9
Required surgery (4 cycles): n = 53
Metastasis: n = 2
Declined further treatment: n = 2
Lost to follow-up: n = 4
Required surgery (5 cycles): n = 9
Switched regimens: n = 7
Required surgery: n = 8
Declined further treatment: n = 4
Lost to follow-up: n = 2
Required surgery (5 cycles): n = 8
Declined further treatment: n = 1
Lost to follow-up: n = 1
Switched regimens: n = 13
Required surgery (3 cycles): n = 5
Required surgery (4 cycles): n = 38
Declined further treatment: n = 5 
Lost to follow-up: n = 3
Switched regimens: n = 9
Required surgery: n = 1
Declined further treatment: n = 4







Withdrew: n = 7
Fig. 1 Study flow chart for comparison of weekly PE and tri‑weekly FEC regimens in treating locally advanced breast cancer. FEC tri‑weekly 5‑fluo‑
rouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, NACT neoadjuvant chemotherapy. #All participants who 
switched chemotherapy regimens had undergone surgery except one in the PE arm that was lost to follow‑up
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In China, delayed detection and a lack of awareness 
of breast cancer have led to a high prevalence of locally 
advanced breast cancer at the initial diagnosis [11, 12]. 
Locally advanced breast cancer with large tumor lesions 
and more node involvement is related with a lower pCR 
rate as compared with early stage or operable breast 
cancer [13, 14]. In the present study, the overall pCR 
rate (12.31%) in the PE arm was comparable to those 
reported previously for taxane–anthracycline-based 
regimens (13.3%–18%) [15, 16]. Specifically, the results 
were similar to those of the ABCSG-14 trial, which 
administered 6 cycles of epirubicin 75 mg/m2 plus doc-
etaxel 75  mg/m2, resulting in overall and breast pCR 
rates of 15.9% and 18.6%, respectively [17]. However, 
the ABCSG-14 trial included patients with diseases at 
any tumor stage, whereas the present study focused 
on those with locally advanced breast cancer who may 
have a poorer prognosis. Additionally, the predominant 
population in the present study was positive for hor-
mone receptor, which was a predictive factor for a low 
response to NACT [18, 19].
In the present study, the pCR rate was higher in the PE 
arm than in the FEC arm, although the difference was not 
significant. However, we must note that more patients in 
the FEC arm switched regimens during the study than 
those in the PE arm (22 vs. 12). When performing the 
intention-to-treat analysis, the high regimen switch rate 
in the FEC arm was a confounder and an indirect indica-
tor of poor disease control.
Although our findings do not support that the weekly 
PE regimen is superior than the tri-weekly FEC regi-
men in terms of the pCR rate, the PE regimen elicited a 
Table 1 Baseline characteristics of  all enrolled patients 
with locally advanced breast cancer
PE weekly paclitaxel–epirubicin regimen, FEC tri-weekly 5-fluorouracil–
epirubicin–cyclophosphamide regimen, ER estrogen receptor, PR progesterone 
receptor, HER2 epidermal growth factor receptor-2, IHC immunohistochemistry
Characteristic FEC arm  
[cases (%)]





 ≤35 5 (3.31) 8 (5.63)
 >35 146 (96.69) 134 (94.37)
Menopausal status 0.263
 Premenopausal 31 (20.53) 22 (15.49)
 Postmenopausal 120 (79.47) 120 (84.51)
Clinical tumor stage 0.075
 T2 106 (70.20) 86 (60.56)
 T3 43 (28.48) 52 (36.62)
 T4 2 (1.32) 4 (2.82)
Clinical nodal status 0.497
 Involved 130 (86.09) 126 (88.73)
 Not involved 21 (13.91) 16 (11.27)
ER/PR status 0.533
 Positive 96 (63.58) 89 (62.68)
 Negative 47 (31.13) 52 (36.62)
 Missing 8 (5.30) 1 (0.70)
HER2 (IHC staining) 0.189
 0/1+ 64 (42.38) 66 (46.48)
 2+ 31 (20.53) 26 (18.31)
 3+ 45 (29.80) 47 (33.10)
Missing 11 (7.28) 3 (2.11)
Table 2 Clinical responses of  patients with  locally 
advanced breast cancer to  neoadjuvant chemotherapy 
(FEC regimen vs. PE regimen) during each assessments
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly 
paclitaxel–epirubicin regimen, cCR clinical complete response, cPR clinical partial 
response, cSD clinical stable disease, cPD clinical progressive disease






FEC arm 151 132 68
 cCR 0 (0.00) 1 (0.76) 3 (4.41)
 cPR 70 (46.36) 76 (57.58) 51 (75.00)
 cSD 67(44.37) 45 (34.09) 13 (19.12)
 cPD 6 (3.97) 7 (5.30) 1 (1.47)
 Missing 8 (5.30) 3 (2.27) 0 (1.47)
PE arm 142 121 49
 cCR 1 (0.70) 6 (4.96) 5 (10.20)
 cPR 97 (68.31) 92 (76.03) 41 (83.67)
 cSD 35 (24.65) 20 (16.53) 2 (4.08)
 cPD 3 (2.11) 3 (2.48) 1 (2.04)
 Missing 6 (4.23) 0 (0.00) 0 (0.00)
Fig. 2 Final assessment of clinical responses of patients with locally 
advanced breast cancer to neoadjuvant chemotherapy (FEC regimen 
vs. PE regimen). FEC tri‑weekly 5‑fluorouracil–epirubicin–cyclophos‑
phamide regimen, PE weekly paclitaxel–epirubicin regimen, cCR 
clinical complete response, cPR clinical partial response, cSD clinical 
stable disease, cPD clinical progressive disease. *P < 0.05
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superior tumor response and down-staging effect in terms 
of the clinical and pathologic evaluations. Our results sug-
gest that the weekly PE regimen can improve disease con-
trol and reduce the extent of surgical resection.
The increased chance of BCS is an important benefit 
of NACT. However, BCS might be difficult for women 
with locally advanced breast cancer, especially Chinese 
women. In the present study, the theoretical BCS rates 
were 27.27% in the FEC arm and 35.38% in the PE arm, 
which were lower than that reported by Amat et al. (over-
all BCS rate of 72.37%) [20]. These disparities could be 
caused by the inclusion of women with breast cancer at 
different stages in their study. The relatively small breast 
volume in Chinese women may also contribute to this 
phenomenon. In the present study, many patients who 
were qualified for BCS declined the surgery. Different 
attitudes towards breast cancer in eastern and west-
ern countries may explain the lower acceptance rate of 
BCS among Chinese women. In addition, the economic 
burden of postoperative radiotherapy and long-term fol-
low-up might contribute to the preference of mastectomy 
over BCS [21–23].
In the present study, the adverse events were compara-
ble in both arms, with more severe neutropenia in the PE 
arm, which could be successfully treated using G-CSF in 
our study and other studies [24, 25].
There are some limitations in the present study. 
Most epidermal growth factor receptor-2 (HER2)-
positive patients in our study could not afford HER2-
targeting therapy and refused further HER2 status 
testing. With this lack of data, we could not carry out 
subgroup analyses to identify any subpopulation that 
was more likely to benefit from the weekly PE regi-
men. Because there were no significant differences in 
terms of the pCR rate at the time of surgery, long-term 
follow-up data will be reported to further assess the 
efficacy of the weekly PE regimen on locally advanced 
breast cancer.
Table 3 Clinical down-staging effects of the FEC and PE regimens on locally advanced breast cancer
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen
a Of the 9 patients, 2 had migrated to other cities and were not restaged, 5 declined further treatment and were not restaged, and 2 were lost to follow-up
b Of the 6 patients, 5 declined further treatment and were not restaged, and 1 was lost to follow-up
T stage FEC arm [cases (%)] P value PE arm [cases (%)] P value
Baseline After NACT Baseline After NACT
Total 151 151 <0.001 142 142 <0.001
0 0 (0.00) 5 (3.31) 0 (0.00) 12 (8.45)
1 0 (0.00) 46 (30.46) 0 (0.00) 62 (43.66)
2 106 (70.20) 77 (50.99) 86 (60.65) 55 (38.73)
3 43 (28.48) 9 (6.62) 52 (36.62) 5 (3.52)
4 2 (1.32) 5 (2.65) 4 (2.82) 2 (1.41)
Missing 0 (0.00) 9a (5.96) 0 (0.00) 6b (4.23)
Table 4 Surgical breast and lymph node management for the FEC and PE arms
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, SLNB sentinel lymph node biopsy
a Required by participants
Surgery type FEC arm [cases (%)] PE arm [cases (%)] P value
Total 132 130
The breast 0.456
 Breast‑conserving surgery 3 (2.27) 4 (3.08)
 Mastectomy 75 (56.82) 66 (50.77)
 Modified radical mastectomy 54 (40.91) 60 (46.15)
Lymph nodes 0.633
 No surgerya 0 (0.00) 1 (0.77)
 SLNBa 1 (0.76) 2 (1.54)
 Level I–II node dissection 28 (21.21) 21 (16.15)
 Level I–III node dissection 86 (65.15) 89 (68.46)
 Level I–III + supraclavicular node dissection 17 (12.88) 17 (13.08)
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Conclusions
This prospective, randomized study suggests that the 
weekly PE regimen is not superior to the tri-weekly FEC 
regimen in treating locally advanced breast cancer in 
terms of pCR. However, the weekly PE regimen is well 
tolerated and has a superior clinical tumor response in 
Chinese women with locally advanced breast cancer. 
Long-term outcomes are needed to confirm the efficacy 
of weekly taxanes in combination with an anthracycline-
based regimen.
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